Every drug has side effects. Some are discovered only after millions of people have taken it. That's where pharmacovigilance comes in — using data analytics to detect safety signals early. The US clinical data analytics market forecast shows that pharmacovigilance is the fastest‑growing application, with a CAGR above 11%. Why? Because regulators (FDA, EMA) are demanding real‑world evidence, and drug companies don't want another Vioxx scandal.

What's new? AI that mines social media, electronic health records, and insurance claims to spot adverse events. Also, natural language processing that reads doctor's notes to find unreported side effects. The US clinical data analytics market analysis notes that the fastest‑growing end‑user segment is pharmaceutical companies, which are hiring armies of data scientists.

But pharmacovigilance is hard. False positives are common, and linking a drug to a rare side effect requires huge datasets and sophisticated statistics.

The bottom line: if you're a drug maker, invest in pharmacovigilance analytics. It's not just compliance — it's good business. A recall can destroy a brand.